Avalo Therapeutics, Inc.

NasdaqCM:AVTX Stock Report

Mkt Cap: US$46.1m

We’ve recently updated our valuation analysis.

Avalo Therapeutics Valuation

Is AVTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVTX?

Other financial metrics that can be useful for relative valuation.

AVTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.9x
Enterprise Value/EBITDA-1.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AVTX's PS Ratio compare to its peers?

The above table shows the PS ratio for AVTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average16.1x
ABEO Abeona Therapeutics
10.1x55.2%US$44.0m
MEIP MEI Pharma
1.1x45.7%US$45.3m
DYAI Dyadic International
17.7x30.6%US$44.3m
BCDA BioCardia
35.6x66.7%US$47.1m
AVTX Avalo Therapeutics
2.7x41.3%US$46.1m

Price-To-Sales vs Peers: AVTX is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (16.1x).


Price to Earnings Ratio vs Industry

How does AVTX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Sales vs Industry: AVTX is good value based on its Price-To-Sales Ratio (2.7x) compared to the US Biotechs industry average (12.8x)


Price to Sales Ratio vs Fair Ratio

What is AVTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: AVTX is expensive based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).


Share Price vs Fair Value

What is the Fair Price of AVTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVTX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AVTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.90
US$10.63
+116.8%
38.7%US$17.00US$5.50n/a4
Jan ’24US$5.04
US$10.63
+110.8%
38.7%US$17.00US$5.50n/a4
Dec ’23US$5.69
US$10.63
+86.7%
38.7%US$17.00US$5.50n/a4
Nov ’23US$6.65
US$11.38
+71.1%
50.1%US$17.00US$4.50n/a4
Oct ’23US$3.32
US$11.38
+242.6%
50.1%US$17.00US$4.50n/a4
Sep ’23US$4.70
US$11.38
+142.0%
50.1%US$17.00US$4.50n/a4
Aug ’23US$3.60
US$43.50
+1,108.3%
69.1%US$84.00US$9.00n/a4
Jul ’23US$6.24
US$42.60
+582.7%
62.4%US$84.00US$9.00n/a5
Jun ’23US$3.84
US$42.60
+1,009.0%
62.4%US$84.00US$9.00n/a5
May ’23US$4.93
US$47.40
+861.5%
52.6%US$84.00US$9.00n/a5
Apr ’23US$10.45
US$47.40
+353.4%
52.6%US$84.00US$9.00n/a5
Mar ’23US$9.82
US$60.00
+510.9%
25.3%US$84.00US$36.00n/a5
Feb ’23US$12.00
US$69.00
+475.0%
14.4%US$84.00US$60.00n/a4
Jan ’23US$20.40
US$72.00
+252.9%
14.9%US$84.00US$60.00US$5.045
Dec ’22US$22.44
US$72.00
+220.9%
14.9%US$84.00US$60.00US$5.695
Nov ’22US$28.68
US$76.80
+167.8%
12.5%US$84.00US$60.00US$6.655
Oct ’22US$27.00
US$76.80
+184.4%
12.5%US$84.00US$60.00US$3.325
Sep ’22US$38.88
US$78.00
+100.6%
13.3%US$84.00US$60.00US$4.704
Aug ’22US$31.92
US$84.00
+163.2%
18.1%US$108.00US$60.00US$3.605
Jul ’22US$40.68
US$81.60
+100.6%
23.5%US$108.00US$48.00US$6.245
Jun ’22US$33.36
US$93.60
+180.6%
33.8%US$144.00US$48.00US$3.845
May ’22US$37.68
US$98.40
+161.1%
32.2%US$144.00US$48.00US$4.935
Apr ’22US$36.60
US$120.00
+227.9%
14.1%US$144.00US$108.00US$10.453
Mar ’22US$44.76
US$120.00
+168.1%
14.1%US$144.00US$108.00US$9.823
Feb ’22US$37.80
US$112.00
+196.3%
22.0%US$144.00US$84.00US$12.003
Jan ’22US$31.68
US$112.00
+253.5%
22.0%US$144.00US$84.00US$20.403

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies